1.98

3.66% 0.07

Lixte Biotechnology Holdings Inc (LIXT)

Overview News Price History Financials Discussions Forecast Stock Split

Lixte Biotechnology Holdings Inc stock is traded at $1.98, with a volume of 7,181. It is up +3.66% in the last 24 hours and up +32.89% over the past month. Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Previous Close:

$1.91

Open:

$1.95

24h Volume:

7,181

Relative Volume:

0.01

Market Cap:

$4.45M

Revenue:

Net Income/Loss:

$-4.69M

P/E Ratio:

-0.5351

EPS:

-3.7

Net Cash Flow:

$-3.81M

1W Performance:

-0.26%

1M Performance:

+32.89%

6M Performance:

-20.32%

1Y Performance:

-5.71%

1-Day Range:

$1.85

$2.14

1-Week Range:

$1.80

$2.65

52-Week Range:

$1.31

$4.40

Lixte Biotechnology Holdings Inc Stock (LIXT) Company Profile

Name

Lixte Biotechnology Holdings Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

310 203 2902

Address

248 ROUTE 25A, EAST SETAUKET

Employee

Twitter

Next Earnings Date

2024-11-07

Latest SEC Filings

LIXT's Discussions on Twitter

Compare LIXT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
LIXT Lixte Biotechnology Holdings Inc	1.98	4.45M	0	-4.69M	-3.81M	-2.33
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Lixte Biotechnology Holdings Inc Stock (LIXT) Latest News

Dec 18, 2024

US Penny Stocks To Watch In December 2024 - Simply Wall St

Dec 18, 2024

Dec 05, 2024

LIXT (Lixte Biotechnology Holdings) 3-Year Sharpe Ratio : -0.39 (As of Dec. 05, 2024) - GuruFocus.com

Dec 05, 2024

Dec 02, 2024

LIXTE Biotechnology inks amendment to cancer drug study agreement - Investing.com

Dec 02, 2024

LIXTE Biotechnology inks amendment to cancer drug study agreement By Investing.com - Investing.com Nigeria

Dec 02, 2024

Lixte Biotechnology Holdings, Inc. Enters into Development Collaboration Agreement with the Netherlands Cancer Institute, Amsterdam - Marketscreener.com

Dec 02, 2024

Nov 23, 2024

Lixte Biotechnology Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 23, 2024

Nov 15, 2024

LIXTW (Lixte Biotechnology Holdings) Accounts Payable & Acc - GuruFocus.com

Nov 15, 2024

Oct 29, 2024

LIXT stock touches 52-week low at $1.53 amid market challenges - Investing.com Australia

Oct 29, 2024

Why VF Corp Shares Are Trading Higher By Around 21%; Here Are 20 Stocks Moving Premarket - Benzinga

Oct 29, 2024

Oct 28, 2024

LIXT stock touches 52-week low at $1.53 amid market challenges By Investing.com - Investing.com South Africa

Oct 28, 2024

Oct 23, 2024

Lixte Biotechnology granted extension to meet Nasdaq listing rules By Investing.com - Investing.com Australia

Oct 23, 2024

Lixte Biotechnology granted extension to meet Nasdaq listing rules - Investing.com

Oct 23, 2024

Oct 09, 2024

Lixte Biotechnology Holdings Inc WT (LIXTW-Q) QuotePress Release - The Globe and Mail

Oct 09, 2024

Oct 01, 2024

LIfT BioSciences raises £10m in first close of Series A to advance first-in-class allogeneic innate cell therapy - GlobeNewswire

Sep 24, 2024

Sep 23, 2024

Should investors be concerned about LYT’s high price-to-sales ratio? - US Post News

Sep 23, 2024

Lilium (NASDAQ:LILM) Earns Overweight Rating from Cantor Fitzgerald - MarketBeat

Sep 23, 2024

Liquidia Co. (NASDAQ:LQDA) Shares Bought by Rhumbline Advisers - Defense World

Sep 23, 2024

Pacer Advisors Inc. Has $16.07 Million Stock Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World

Sep 23, 2024

Lipella Pharmaceuticals Inc’s Market Journey: Closing Weak at 0.41, Down -2.35 - The Dwinnex

Sep 23, 2024

Renaissance Technologies LLC Sells 2,000 Shares of LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 23, 2024

Sep 22, 2024

Texas Permanent School Fund Corp Trims Position in Liquidity Services, Inc. (NASDAQ:LQDT) - Defense World

Sep 22, 2024

Sep 21, 2024

First Eagle Investment Management LLC Increases Stake in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024

Huber Capital Management LLC Acquires 241,814 Shares of Lyft, Inc. (NASDAQ:LYFT) - Defense World

Sep 21, 2024

Acadian Asset Management LLC Cuts Position in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024

Quest Partners LLC Invests $28,000 in LSI Industries Inc. (NASDAQ:LYTS) - Defense World

Sep 21, 2024

Sep 19, 2024

Investors who lost money with shares of Liquidia Corporation - openPR

Sep 19, 2024

Sep 18, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Liquidia CorporationLQDA - Kilgore News Herald

Sep 18, 2024

Sep 11, 2024

Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing - Yahoo Finance

Sep 11, 2024

Sep 10, 2024

Biotech Steals The Show Following Pre-Clinical Data Announcement - MSN

Sep 10, 2024

Sep 05, 2024